117 related articles for article (PubMed ID: 1101842)
1. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients.
Quitkin F; Rifkin A; Klein DF
Arch Gen Psychiatry; 1975 Oct; 32(10):1276-81. PubMed ID: 1101842
[TBL] [Abstract][Full Text] [Related]
2. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
[TBL] [Abstract][Full Text] [Related]
3. High doses of fluphenazine enanthate in schizophrenia. A controlled study.
Dencker SJ; Johansson R; Lundin L; Malm U
Acta Psychiatr Scand; 1978 May; 57(5):405-14. PubMed ID: 354329
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
[TBL] [Abstract][Full Text] [Related]
5. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
[No Abstract] [Full Text] [Related]
6. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
[TBL] [Abstract][Full Text] [Related]
7. High vs standard dosage fluphenazine HCL in acute schizophrenia.
Donlon PT; Meadow A; Tupin JP; Wahba M
J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
[TBL] [Abstract][Full Text] [Related]
8. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
[TBL] [Abstract][Full Text] [Related]
9. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
Schooler NR; Levine J
Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
[TBL] [Abstract][Full Text] [Related]
10. Very high dosage fluphenazine for nonchronic treatment-refractory patients.
Rifkin A; Quitkin F; Carrillo C; Klein DF
Arch Gen Psychiatry; 1971 Nov; 25(5):398-403. PubMed ID: 5133813
[No Abstract] [Full Text] [Related]
11. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
12. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
MacCrimmon DJ; Saxena B; Foley P; Grof P
Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
[TBL] [Abstract][Full Text] [Related]
13. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
[TBL] [Abstract][Full Text] [Related]
14. A trial of fluphenazine enanthate in chronic schizophrenia.
Millar J; Daniel GR
Br J Psychiatry; 1967 Dec; 113(505):1431-2. PubMed ID: 4865296
[No Abstract] [Full Text] [Related]
15. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
[TBL] [Abstract][Full Text] [Related]
16. Fluphenazine plasma levels, dosage, efficacy, and side effects.
Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
[TBL] [Abstract][Full Text] [Related]
17. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
[TBL] [Abstract][Full Text] [Related]
18. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
19. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
20. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
Saletu B; Küfferle B; Grünberger J; Földes P; Topitz A; Anderer P
Neuropsychobiology; 1994; 29(3):125-35. PubMed ID: 7912819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
